Global Health Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Strong return on equity (ROE 15.2%)
- Efficient capital deployment (ROCE 17.4%)
- Low debt relative to equity (D/E 0.3x)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
MEDANTA · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 33.05% | 33.04% | 33.04% | 33.04% | 33.03% | 33.03% |
| FII | 11.36% | 12.10% | 12.94% | 12.21% | 12.48% | 11.76% |
| DII | 11.15% | 10.25% | 10.57% | 11.11% | 10.51% | 11.93% |
| Public | 44.45% | 44.60% | 43.44% | 43.64% | 43.98% | 43.28% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026
Dividend - Re 0.50 Per Share
To consider and approve the financial results for the period ended Jun 30, 2026
To consider and approve the financial results for the quarter and year ended March 31, 2026 and recommendation of final dividend, if any subject to shareholders approval.
Dividend - Re 0.50 Per Share
Latest News
All newsSTL Global reports Q1FY26 financial results
*STL Global reports Q1FY26 financial results*. The company has submitted its financial results for the quarter ended June 30, 2026. Key performance numbers and guidance will influence near-term trading sentiment. Investors await details on revenue, profit margins, and order book. 📊 *STOCKS:* $STL | 🏢 *SECTOR:* CapitalMarkets | #HIGHIMPACT #Earnings
India's services growth hits six-month high on strong domestic demand
*India's services growth hits six-month high on strong domestic demand.* The S&P Global Services PMI rose to **61.0** in May, the highest since November, driven by robust domestic demand. New orders surged with a sharp increase in business confidence. Output and employment expanded at faster rates. 📊 *STOCKS:* | 🏢 *SECTOR:* Macro | #HIGHIMPACT #PMI
Medanta to acquire 10,560 sqm land in Ghaziabad for expansion
*Medanta to acquire 10,560 sqm land in Ghaziabad for expansion.* The acquisition supports its plan to expand healthcare services in Uttar Pradesh. The land parcel is strategically located to enhance patient access and operational capacity. This move signals long-term growth focus in North India. 📊 *STOCKS:* MEDANTA | 🏢 *SECTOR:* Healthcare | #MEDIUMIMPACT #Expansion
Mastek partners with Innovaccer for AI healthcare push
*Mastek partners with Innovaccer for AI healthcare push.* The collaboration aims to accelerate AI-driven solutions in healthcare. While financial details weren’t disclosed, the strategic move enhances Mastek’s footprint in the global health tech space. **No immediate revenue impact** expected in FY25. 📊 *STOCKS:* $MASTEK | 🏢 *SECTOR:* IT | #MEDIUMIMPACT #Partnership
Avio appoints Sandeep Pandya to lead global healthcare expansion
*Avio appoints Sandeep Pandya to lead global healthcare expansion.* The move signals a strategic push into international diagnostics markets. Pandya brings **20+ years** of global healthcare experience. This leadership hire aims to scale the company’s footprint in emerging regions. 📊 *STOCKS:* AVIO | 🏢 *SECTOR:* Corporate | #MEDIUMIMPACT #Leadership
India services growth hits 3-month high but quarterly low since 2022
*India services growth hits 3-month high but quarterly low since 2022*. The S&P Global Services PMI rose to **55.1** in March, up from **53.8** in February, signaling a rebound in expansion. However, the average quarterly reading was the weakest since 2022, indicating uneven recovery. Growth momentum remains fragile despite recent improvement. 📊 *STOCKS:* | 🏢 *SECTOR:* Macro | #MEDIUMIMPACT #PMI
Global Health receives ESG rating from Crisil
*Global Health receives ESG rating from Crisil* — Crisil ESG Ratings & Analytics Limited has assigned an ESG rating to Global Health Limited under SEBI's disclosure norms. The rating reflects the company’s environmental, social, and governance practices. This is a compliance-related disclosure with no immediate financial impact. 📊 *STOCKS:* $MEDANTA | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #ESG
STL Global to hold shareholder meeting on Sep 30, 2026
*STL Global to hold shareholder meeting on Sep 30, 2026.* The meeting is scheduled for **September 30, 2026**, as per an NSE filing. No specific agenda details were disclosed. This is a routine corporate event with no immediate financial impact. 📊 *STOCKS:* $STL | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #ShareholderMeeting
Global Health Limited issues general updates
*Global Health Limited issues general updates.* The company filed a routine corporate update with the NSE. No specific financial or operational details were disclosed. Such filings typically contain administrative or procedural information. 📊 *STOCKS:* $GLOBALHEALTH | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #corporate
Global Health to host investor meet for updates
*Global Health to host investor meet for updates.* The company will conduct an analyst and institutional investor meet to discuss business developments. Specific date and agenda details will be shared via official channels. Investors await strategic insights and operational updates. 📊 *STOCKS:* MEDANTA | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #InvestorMeet
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1.1K Cr 2.0% | ₹1.1K Cr 6.6% | ₹1.0K Cr 10.7% | ₹931 Cr 1.3% | ₹943 Cr 1.5% | ₹957 Cr 11.1% | ₹861 Cr 6.4% | ₹809 Cr |
| Op. Profit | ₹217 Cr 6.1% | ₹231 Cr 6.5% | ₹247 Cr 9.8% | ₹225 Cr 5.5% | ₹238 Cr 4.4% | ₹228 Cr 22.6% | ₹186 Cr 3.9% | ₹179 Cr |
| OPM | 19.0% 9.5% | 21.0% 12.5% | 24.0% 0.0% | 24.0% 4.0% | 25.0% 4.2% | 24.0% 9.1% | 22.0% 0.0% | 22.0% |
| Net Profit | ₹95 Cr 39.9% | ₹158 Cr 0.6% | ₹159 Cr 57.4% | ₹101 Cr 29.4% | ₹143 Cr 9.2% | ₹131 Cr 23.6% | ₹106 Cr 16.5% | ₹127 Cr |
| EPS (₹) | 3.54 39.9% | 5.89 0.5% | 5.92 56.6% | 3.78 28.9% | 5.32 9.2% | 4.87 23.0% | 3.96 16.5% | 4.74 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹4.4K Cr 19.4% | ₹3.7K Cr 12.7% | ₹3.3K Cr 20.8% | ₹2.7K Cr 25.1% | ₹2.2K Cr 49.8% | ₹1.4K Cr 3.5% | ₹1.5K Cr 3.0% | ₹1.5K Cr 8.4% | ₹1.3K Cr 2.8% | ₹1.4K Cr |
| Expenses | ₹3.5K Cr 24.0% | ₹2.8K Cr 13.8% | ₹2.5K Cr 19.0% | ₹2.1K Cr 21.3% | ₹1.7K Cr 36.7% | ₹1.3K Cr 4.5% | ₹1.3K Cr 2.0% | ₹1.3K Cr 5.3% | ₹1.2K Cr 12.7% | ₹1.1K Cr |
| Op. Profit | ₹930 Cr 5.0% | ₹886 Cr 9.5% | ₹809 Cr 27.0% | ₹637 Cr 39.1% | ₹458 Cr 132.5% | ₹197 Cr 2.6% | ₹192 Cr 11.6% | ₹172 Cr 37.6% | ₹125 Cr 58.5% | ₹301 Cr |
| OPM | 21.0% 12.5% | 24.0% 4.0% | 25.0% 4.2% | 24.0% 14.3% | 21.0% 50.0% | 14.0% 7.7% | 13.0% 8.3% | 12.0% 33.3% | 9.0% 59.1% | 22.0% |
| Other Income | ₹98 Cr 237.9% | ₹29 Cr 61.3% | ₹75 Cr 53.1% | ₹49 Cr 25.6% | ₹39 Cr 25.8% | ₹31 Cr 29.5% | ₹44 Cr 12.0% | ₹50 Cr 2.0% | ₹49 Cr 8.9% | ₹45 Cr |
| Interest | ₹90 Cr 21.6% | ₹74 Cr 11.9% | ₹84 Cr 2.3% | ₹86 Cr 0.0% | ₹86 Cr 17.8% | ₹73 Cr 28.1% | ₹57 Cr 50.0% | ₹38 Cr 35.7% | ₹28 Cr 100.0% | ₹14 Cr |
| Depreciation | ₹223 Cr 14.9% | ₹194 Cr 12.1% | ₹173 Cr 15.3% | ₹150 Cr 15.4% | ₹130 Cr 5.7% | ₹123 Cr 7.0% | ₹115 Cr 12.7% | ₹102 Cr 18.6% | ₹86 Cr 22.9% | ₹70 Cr |
| PBT | ₹715 Cr 10.5% | ₹647 Cr 3.2% | ₹627 Cr 39.6% | ₹449 Cr 59.8% | ₹281 Cr 778.1% | ₹32 Cr 50.0% | ₹64 Cr 22.9% | ₹83 Cr 38.3% | ₹60 Cr 77.1% | ₹262 Cr |
| Tax % | 23.0% 11.5% | 26.0% 8.3% | 24.0% 11.1% | 27.0% 10.0% | 30.0% 172.7% | 11.0% 74.4% | 43.0% 13.2% | 38.0% 15.6% | 45.0% 28.6% | 35.0% |
| Net Profit | ₹554 Cr 15.2% | ₹481 Cr 0.6% | ₹478 Cr 46.6% | ₹326 Cr 66.3% | ₹196 Cr 575.9% | ₹29 Cr 19.4% | ₹36 Cr 29.4% | ₹51 Cr 54.5% | ₹33 Cr 80.6% | ₹170 Cr |
| EPS (₹) | 20.7 15.5% | 17.92 0.6% | 17.81 46.5% | 12.16 56.9% | 7.75 568.1% | 1.16 21.1% | 1.47 29.7% | 2.09 53.7% | 1.36 96.1% | 35.1 |
| Div Payout | 2.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹54 Cr 0.0% | ₹54 Cr 0.0% | ₹54 Cr 0.0% | ₹54 Cr 5.9% | ₹51 Cr 2.0% | ₹50 Cr 2.0% | ₹49 Cr 0.0% | ₹49 Cr 2.1% | ₹48 Cr 0.0% | ₹48 Cr |
| Reserves | ₹3.7K Cr 9.6% | ₹3.3K Cr 16.9% | ₹2.9K Cr 20.1% | ₹2.4K Cr 51.8% | ₹1.6K Cr 17.4% | ₹1.3K Cr 2.5% | ₹1.3K Cr 4.3% | ₹1.2K Cr 9.7% | ₹1.1K Cr 16.4% | ₹976 Cr |
| Borrowings | ₹945 Cr 31.6% | ₹718 Cr 10.5% | ₹802 Cr 28.5% | ₹1.1K Cr 1.2% | ₹1.1K Cr 19.1% | ₹931 Cr 0.2% | ₹929 Cr 18.0% | ₹787 Cr 72.6% | ₹456 Cr 176.4% | ₹165 Cr |
| Other Liabilities | ₹757 Cr 14.4% | ₹662 Cr 15.7% | ₹572 Cr 4.6% | ₹547 Cr 29.9% | ₹421 Cr 10.8% | ₹380 Cr 2.1% | ₹388 Cr 11.8% | ₹347 Cr 1.2% | ₹343 Cr 16.3% | ₹295 Cr |
| Total Liabilities | ₹5.4K Cr 13.5% | ₹4.8K Cr 11.4% | ₹4.3K Cr 4.5% | ₹4.1K Cr 30.2% | ₹3.1K Cr 16.8% | ₹2.7K Cr 1.1% | ₹2.7K Cr 9.7% | ₹2.4K Cr 22.5% | ₹2.0K Cr 33.6% | ₹1.5K Cr |
Assets | ||||||||||
| Fixed Assets | ₹3.2K Cr 27.2% | ₹2.5K Cr 12.4% | ₹2.2K Cr 9.1% | ₹2.0K Cr 15.4% | ₹1.8K Cr 9.9% | ₹1.6K Cr 5.1% | ₹1.7K Cr 42.6% | ₹1.2K Cr 9.1% | ₹1.1K Cr 19.7% | ₹914 Cr |
| CWIP | ₹318 Cr 40.3% | ₹533 Cr 37.4% | ₹388 Cr 18.7% | ₹327 Cr 25.5% | ₹439 Cr 5.4% | ₹464 Cr 21.5% | ₹382 Cr 42.6% | ₹666 Cr 110.1% | ₹317 Cr 2541.7% | ₹12 Cr |
| Investments | ₹3 Cr 0.0% | ₹3 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹1.9K Cr 10.1% | ₹1.7K Cr 3.6% | ₹1.7K Cr 3.7% | ₹1.7K Cr 84.9% | ₹930 Cr 51.2% | ₹615 Cr 5.9% | ₹581 Cr 1.9% | ₹570 Cr 0.5% | ₹573 Cr 2.5% | ₹559 Cr |
| Total Assets | ₹5.4K Cr 13.5% | ₹4.8K Cr 11.4% | ₹4.3K Cr 4.5% | ₹4.1K Cr 30.2% | ₹3.1K Cr 16.8% | ₹2.7K Cr 1.1% | ₹2.7K Cr 9.7% | ₹2.4K Cr 22.5% | ₹2.0K Cr 33.6% | ₹1.5K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹714 Cr 14.4% | ₹624 Cr 2.0% | ₹612 Cr 5.1% | ₹645 Cr 107.4% | ₹311 Cr 28.5% | ₹242 Cr 38.3% | ₹175 Cr 5.4% | ₹166 Cr 163.5% | ₹63 Cr 72.4% | ₹228 Cr |
| Investing CF | ₹-1.1K Cr 51.0% | ₹-721 Cr 63.5% | ₹-441 Cr 28.9% | ₹-342 Cr 18.8% | ₹-421 Cr 76.2% | ₹-239 Cr 174.7% | ₹-87 Cr 65.1% | ₹-249 Cr 260.9% | ₹-69 Cr 71.4% | ₹-241 Cr |
| Financing CF | ₹272 Cr 380.4% | ₹-97 Cr 81.1% | ₹-514 Cr 248.6% | ₹346 Cr 116.3% | ₹160 Cr 297.5% | ₹-81 Cr 8000.0% | ₹-1 Cr 101.0% | ₹97 Cr 977.8% | ₹9 Cr 228.6% | ₹-7 Cr |
| Net Cash Flow | ₹-103 Cr 46.9% | ₹-194 Cr 43.4% | ₹-343 Cr 152.9% | ₹648 Cr 1196.0% | ₹50 Cr 164.1% | ₹-78 Cr 189.7% | ₹87 Cr 521.4% | ₹14 Cr 366.7% | ₹3 Cr 115.0% | ₹-20 Cr |
| Free Cash Flow | ₹-123 Cr 211.8% | ₹110 Cr 67.2% | ₹335 Cr 18.1% | ₹409 Cr 976.3% | ₹38 Cr 62.0% | ₹100 Cr 869.2% | ₹-13 Cr 90.2% | ₹-133 Cr 64.2% | ₹-81 Cr 214.1% | ₹71 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 34d 17.2% | 29d 20.8% | 24d 7.7% | 26d 13.3% | 30d 11.8% | 34d 5.6% | 36d 12.2% | 41d 0.0% | 41d 105.0% | 20d |
| Inventory Days | 29d 3.6% | 28d 12.5% | 32d 8.6% | 35d 2.8% | 36d 14.3% | 42d 2.3% | 43d 65.4% | 26d 0.0% | 26d 7.1% | 28d |
| Days Payable | 89d 9.9% | 81d 10.0% | 90d 21.1% | 114d 26.7% | 90d 34.8% | 138d 6.1% | 147d 3.5% | 142d 14.5% | 124d 34.8% | 92d |
| Cash Conv. Cycle | -26d 8.3% | -24d 29.4% | -34d 34.6% | -52d 116.7% | -24d 61.3% | -62d 7.5% | -67d 10.7% | -75d 33.9% | -56d 24.4% | -45d |
| Working Capital Days | -7d 66.7% | -21d 34.4% | -32d 13.5% | -37d 85.0% | -20d 58.3% | -48d 54.8% | -31d 72.2% | -18d 45.5% | -33d 43.5% | -23d |
| ROCE | 17.0% 15.0% | 20.0% 0.0% | 20.0% 17.6% | 17.0% 13.3% | 15.0% 200.0% | 5.0% 16.7% | 6.0% 0.0% | 6.0% | — | — |
Source: Screener.in · Lower days = better efficiency